ID

32749

Descrizione

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4); ODM derived from: https://clinicaltrials.gov/show/NCT00676338

collegamento

https://clinicaltrials.gov/show/NCT00676338

Keywords

versioni (1)
  1. 14/11/18 14/11/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

14 novembre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes Mellitus NCT00676338

Inglese

Eligibility Type 2 Diabetes Mellitus NCT00676338

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
have type 2 diabetes and are treated with diet and exercise alone.
Descrizione

Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Exercise

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2]
C0012159
UMLS CUI [3]
C0015259
at least 18 years of age.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
hba1c between 7.1% and 11.0%, inclusive.
Descrizione

Hemoglobin A1c measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) of 23 kg/m2 to 45 kg/m2, inclusive.
Descrizione

Body mass index

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1305855
have a history of stable body weight (not varying by >5% for at least 3 months prior to screening).
Descrizione

Stable body weight | Variability Percentage Timespan

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0517386
UMLS CUI [2,1]
C2827666
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C0872291
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
ave history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty
Descrizione

Heart Disease | Myocardial Infarction | Cardiac Arrhythmia | Angina, Unstable | Congestive heart failure Moderate | Congestive heart failure Severe | Coronary Artery Bypass Surgery | Angioplasty

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0027051
UMLS CUI [3]
C0003811
UMLS CUI [4]
C0002965
UMLS CUI [5,1]
C0018802
UMLS CUI [5,2]
C0205081
UMLS CUI [6,1]
C0018802
UMLS CUI [6,2]
C0205082
UMLS CUI [7]
C0010055
UMLS CUI [8]
C0162577
have a history of renal transplantation or are currently receiving renal dialysis
Descrizione

Kidney Transplantation | Dialysis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0022671
UMLS CUI [2]
C0011946
have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
Descrizione

Malignant Neoplasms | Malignant Neoplasm Untreated | Cancer Remission | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of prostate

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0006826
UMLS CUI [2,2]
C0332155
UMLS CUI [3]
C0687702
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007117
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0553723
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0851140
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0154088
have history of severe gi disorder (e.g., gastroparesis)
Descrizione

Gastrointestinal Disease Severe | Gastroparesis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0017178
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0152020
have a history of acute or chronic pancreatitis.
Descrizione

Pancreatitis | Pancreatitis, Chronic

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0030305
UMLS CUI [2]
C0149521
have active proliferative retinopathy.
Descrizione

Proliferative retinopathy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0339467
have been treated with drugs that promote weight loss (e.g., xenical®[orlistat], meridia® [sibutramine], acomplia® [rimonabant], acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
Descrizione

Weight-Loss Agents | Xenical | orlistat | Meridia | sibutramine | Acomplia | rimonabant | Phenylpropanolamine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0376606
UMLS CUI [2]
C0732649
UMLS CUI [3]
C0076275
UMLS CUI [4]
C0635898
UMLS CUI [5]
C0074493
UMLS CUI [6]
C2002731
UMLS CUI [7]
C1142933
UMLS CUI [8]
C0031495
have been treated with any antidiabetic agent for more than 7 days within 3 months prior to screening.
Descrizione

Antidiabetics

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0935929
have had an organ transplant.
Descrizione

Organ Transplantation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0029216
have previously completed or discontinued study drug in this study, withdrawn from this study or any other study investigating exenatide once weekly.
Descrizione

Study Subject Participation Status | Investigational New Drug Completed | Investigational New Drug Discontinued | Patient withdrawn from trial | exenatide

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C0205197
UMLS CUI [3,1]
C0013230
UMLS CUI [3,2]
C1444662
UMLS CUI [4]
C0422727
UMLS CUI [5]
C0167117
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Descrizione

Pharmaceutical Preparation Approval Lacking

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205540
UMLS CUI [1,3]
C0332268
are currently enrolled in any other clinical study.
Descrizione

Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00676338

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Exercise
Item
have type 2 diabetes and are treated with diet and exercise alone.
boolean
C0011860 (UMLS CUI [1])
C0012159 (UMLS CUI [2])
C0015259 (UMLS CUI [3])
Age
Item
at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c between 7.1% and 11.0%, inclusive.
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) of 23 kg/m2 to 45 kg/m2, inclusive.
boolean
C1305855 (UMLS CUI [1])
Stable body weight | Variability Percentage Timespan
Item
have a history of stable body weight (not varying by >5% for at least 3 months prior to screening).
boolean
C0517386 (UMLS CUI [1])
C2827666 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0872291 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Heart Disease | Myocardial Infarction | Cardiac Arrhythmia | Angina, Unstable | Congestive heart failure Moderate | Congestive heart failure Severe | Coronary Artery Bypass Surgery | Angioplasty
Item
ave history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty
boolean
C0018799 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0003811 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0018802 (UMLS CUI [5,1])
C0205081 (UMLS CUI [5,2])
C0018802 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C0010055 (UMLS CUI [7])
C0162577 (UMLS CUI [8])
Kidney Transplantation | Dialysis
Item
have a history of renal transplantation or are currently receiving renal dialysis
boolean
C0022671 (UMLS CUI [1])
C0011946 (UMLS CUI [2])
Malignant Neoplasms | Malignant Neoplasm Untreated | Cancer Remission | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of prostate
Item
have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
boolean
C0006826 (UMLS CUI [1])
C0006826 (UMLS CUI [2,1])
C0332155 (UMLS CUI [2,2])
C0687702 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0553723 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0851140 (UMLS CUI [6,2])
C1705847 (UMLS CUI [7,1])
C0154088 (UMLS CUI [7,2])
Gastrointestinal Disease Severe | Gastroparesis
Item
have history of severe gi disorder (e.g., gastroparesis)
boolean
C0017178 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0152020 (UMLS CUI [2])
Pancreatitis | Pancreatitis, Chronic
Item
have a history of acute or chronic pancreatitis.
boolean
C0030305 (UMLS CUI [1])
C0149521 (UMLS CUI [2])
Proliferative retinopathy
Item
have active proliferative retinopathy.
boolean
C0339467 (UMLS CUI [1])
Weight-Loss Agents | Xenical | orlistat | Meridia | sibutramine | Acomplia | rimonabant | Phenylpropanolamine
Item
have been treated with drugs that promote weight loss (e.g., xenical®[orlistat], meridia® [sibutramine], acomplia® [rimonabant], acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
boolean
C0376606 (UMLS CUI [1])
C0732649 (UMLS CUI [2])
C0076275 (UMLS CUI [3])
C0635898 (UMLS CUI [4])
C0074493 (UMLS CUI [5])
C2002731 (UMLS CUI [6])
C1142933 (UMLS CUI [7])
C0031495 (UMLS CUI [8])
Antidiabetics
Item
have been treated with any antidiabetic agent for more than 7 days within 3 months prior to screening.
boolean
C0935929 (UMLS CUI [1])
Organ Transplantation
Item
have had an organ transplant.
boolean
C0029216 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drug Completed | Investigational New Drug Discontinued | Patient withdrawn from trial | exenatide
Item
have previously completed or discontinued study drug in this study, withdrawn from this study or any other study investigating exenatide once weekly.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0013230 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C0422727 (UMLS CUI [4])
C0167117 (UMLS CUI [5])
Pharmaceutical Preparation Approval Lacking
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013227 (UMLS CUI [1,1])
C0205540 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
Study Subject Participation Status
Item
are currently enrolled in any other clinical study.
boolean
C2348568 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial